DOP2010000078A - Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3 - Google Patents

Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3

Info

Publication number
DOP2010000078A
DOP2010000078A DO2010000078A DO2010000078A DOP2010000078A DO P2010000078 A DOP2010000078 A DO P2010000078A DO 2010000078 A DO2010000078 A DO 2010000078A DO 2010000078 A DO2010000078 A DO 2010000078A DO P2010000078 A DOP2010000078 A DO P2010000078A
Authority
DO
Dominican Republic
Prior art keywords
histamine
isoindolinona
azaciclilisoquinolinona
antagonists
derivatives
Prior art date
Application number
DO2010000078A
Other languages
English (en)
Inventor
Jonathan Laird Gross
Albert Jean Robichaud
Dahui Zhou
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of DOP2010000078A publication Critical patent/DOP2010000078A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto de formula I y su uso para el tratamiento de un trastorno del sistema nervioso central relacionado con, o que se ve afectado por, el receptor de la histamina-3.
DO2010000078A 2007-09-12 2010-03-11 Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3 DOP2010000078A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99355407P 2007-09-12 2007-09-12

Publications (1)

Publication Number Publication Date
DOP2010000078A true DOP2010000078A (es) 2010-04-15

Family

ID=40261508

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000078A DOP2010000078A (es) 2007-09-12 2010-03-11 Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3

Country Status (23)

Country Link
US (1) US20090069370A1 (es)
EP (1) EP2200998A1 (es)
JP (1) JP2010539178A (es)
KR (1) KR20100054852A (es)
CN (1) CN101842366A (es)
AP (1) AP2010005199A0 (es)
AU (1) AU2008298983A1 (es)
BR (1) BRPI0816806A2 (es)
CA (1) CA2699383A1 (es)
CL (1) CL2008002708A1 (es)
CO (1) CO6300951A2 (es)
CR (1) CR11309A (es)
DO (1) DOP2010000078A (es)
EA (1) EA201000319A1 (es)
EC (1) ECSP10010032A (es)
MA (1) MA31700B1 (es)
MX (1) MX2010002899A (es)
NI (1) NI201000035A (es)
PA (1) PA8795601A1 (es)
PE (1) PE20090679A1 (es)
TN (1) TN2010000107A1 (es)
TW (1) TW200918062A (es)
WO (1) WO2009036117A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
JP2011213700A (ja) * 2010-04-02 2011-10-27 Nishizaki Soyaku Kenkyusho:Kk 認知症改善用組成物
TW201206889A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
JP5968307B2 (ja) 2010-05-11 2016-08-10 サノフイ 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用
AR081034A1 (es) 2010-05-11 2012-05-30 Sanofi Aventis Derivados de n-heteroaril tetrahidro-isoquinolina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
AR081383A1 (es) 2010-05-11 2012-08-29 Sanofi Aventis N-heteroaril bipirrolidin carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades del sistema nervioso central.
EP2569297A1 (en) 2010-05-11 2013-03-20 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
US9295531B2 (en) 2011-06-13 2016-03-29 Dentsply International Inc. Collagen coated article
EP2535062A1 (en) 2011-06-13 2012-12-19 Dentsply IH AB Collagen coated article
RS60660B1 (sr) * 2011-11-30 2020-09-30 Hoffmann La Roche Novi biciklični derivati dihidroizohinolin-1-ona
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
JP6450755B2 (ja) 2013-10-29 2019-01-09 武田薬品工業株式会社 複素環化合物
CN112209876B (zh) * 2020-10-15 2022-08-26 华侨大学 一种3-三氟甲基异喹啉酮衍生物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
SE7907121L (sv) * 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
WO1998013364A1 (fr) * 1996-09-25 1998-04-02 Yamanouchi Pharmaceutical Co., Ltd. Derives de 2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinoline ou compositions medicinales obtenues
US6541499B1 (en) * 1997-05-01 2003-04-01 Eli Lilly And Company Antithrombotic agents
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
DK1771450T5 (da) * 2004-05-14 2012-01-09 Millennium Pharm Inc Forbindelser og fremgangsmåder til inhibering af mitotisk progression ved inhibering af AURORA-kinase
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
SE0401970D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1848696A1 (en) * 2005-01-21 2007-10-31 Schering Corporation Imidazole and benzimidazole derivates useful as histamine h3 antagonists
WO2006113140A2 (en) * 2005-04-15 2006-10-26 Elan Pharmaceuticals, Inc. Novel compounds useful for bradykinin b1 receptor antagonism
US8143284B2 (en) * 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators

Also Published As

Publication number Publication date
CO6300951A2 (es) 2011-07-21
EP2200998A1 (en) 2010-06-30
KR20100054852A (ko) 2010-05-25
TW200918062A (en) 2009-05-01
JP2010539178A (ja) 2010-12-16
NI201000035A (es) 2010-07-15
TN2010000107A1 (fr) 2011-09-26
AU2008298983A1 (en) 2009-03-19
CN101842366A (zh) 2010-09-22
PA8795601A1 (es) 2009-05-15
CR11309A (es) 2010-04-07
US20090069370A1 (en) 2009-03-12
CA2699383A1 (en) 2009-03-19
BRPI0816806A2 (pt) 2015-03-10
AP2010005199A0 (en) 2010-04-30
MX2010002899A (es) 2010-04-09
ECSP10010032A (es) 2010-08-31
EA201000319A1 (ru) 2010-10-29
CL2008002708A1 (es) 2008-10-10
PE20090679A1 (es) 2009-05-28
WO2009036117A1 (en) 2009-03-19
MA31700B1 (fr) 2010-09-01

Similar Documents

Publication Publication Date Title
CO6300951A2 (es) Derivados de azaciclilisoquinolinona e- isoindolinona como antagonistas de la histamina-3
CO6300955A2 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina -3
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
UY33379A (es) Compuestos de morfolina
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
BRPI0907382B8 (pt) antagonista de receptor de opioide seletivo capa, seu uso e composição farmacêutica que o compreende
CO6260091A2 (es) Derivados de iminopiridina y su uso
CL2008002767A1 (es) Compuestos derivados de heterociclico triciclico; composicion farmaceutica; y su uso para el tratamiento de un trastorno mediado por serotonina tal como obesidad, esquizofrenia y disfuncion cognitiva.
PA8781601A1 (es) " derivados de azaciclilbenzamida como antagonistas de histamina-3
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
BR112016012552A8 (pt) derivado de cromona como um antagonista do receptor d3 de dopamina, seu uso e sua composição farmacêutica
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
ECSP067096A (es) Metabolitos de indolilalquilamina como ligandos 5-hidroxitriptamina-6
PA8814801A1 (es) Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
UY31931A (es) Compuestos de diarilo y uso de los mismos
CU20100047A7 (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3